Although patients with AMD do exhibit higher serum levels of activation products C3d, Ba, C3a, C5a, SC5b‐9; C3, C4, FB, and FD, allowing for a systemic impact of genetic changes on AMD, local complement activation and the correct regulation of that activated complement are being described as critical to disease progression.175, 184, 185, 186. This evidence concerns the gene ELP1 and age-related macular degeneration.